Qube Research & Technologies LTD Replimune Group, Inc. Transaction History

Qube Research & Technologies LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$6.87 - $9.31 $1.19 Million - $1.62 Million	-173,494 Reduced 43.95%	221,222 $1.81 Million
Q4 2023 Feb 13, 2024	BUY	$6.75 - $16.18 $2.66 Million - $6.39 Million	394,716 New	394,716 $3.33 Million
Q1 2023 May 15, 2023	BUY	$17.48 - $29.09 $1.73 Million - $2.89 Million	99,182 New	99,182 $1.75 Million
Q2 2022 Aug 15, 2022	SELL	$13.32 - $19.98 $653,878 - $980,818	-49,090 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$15.24 - $29.75 $748,131 - $1.46 Million	49,090 New	49,090 $834,000
Q4 2021 Feb 01, 2022	SELL	$25.43 - $34.25 $181,341 - $244,236	-7,131 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$28.98 - $39.54 $206,656 - $281,959	7,131 New	7,131 $211,000
Q2 2021 Aug 13, 2021	SELL	$28.5 - $39.37 $365,341 - $504,684	-12,819 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$30.22 - $45.57 $387,390 - $584,161	12,819 New	12,819 $391,000

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $694M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.